Nautilus Biotechnology (NAUT) Short-term Investments (2020 - 2026)

Nautilus Biotechnology has disclosed Short-term Investments across 7 years of filings, most recently posting $81.2 million for Q1 2026.

• Short-term Investments for Q1 2026 came in at $81.2 million, down 23.04% year-over-year; the trailing twelve-month figure through Mar 2026 was $81.2 million (down 23.04% YoY), and the FY2025 annual result was $91.0 million, down 10.98% from the prior year.
• Short-term Investments came in at $81.2 million for Q1 2026 at Nautilus Biotechnology, down from $91.0 million in the prior quarter.
• In the past five years, Short-term Investments ranged from a high of $155.6 million in Q1 2024 to a low of $69.0 million in Q3 2022.
• The 5-year median for Short-term Investments is $105.6 million (2025), against an average of $107.8 million.
• Across the five-year window, Short-term Investments tumbled 56.31% in 2022 and jumped 120.19% in 2023, its largest moves.
• Nautilus Biotechnology's Short-term Investments stood at $69.9 million in 2022, then surged by 120.19% to $154.0 million in 2023, then slumped by 33.61% to $102.2 million in 2024, then fell by 10.98% to $91.0 million in 2025, then decreased by 10.74% to $81.2 million in 2026.
• The last three Short-term Investments figures came in at $81.2 million (Q1 2026), $91.0 million (Q4 2025), and $107.6 million (Q3 2025), per Business Quant data.